文献速递肺栓塞与肺血管病

肺动脉高压药物试验靶向的新机制

Novel Mechanisms Targeted by Drug Trials in Pulmonary Arterial Hypertension.
PubMed 文献 · Chest · 2021-10-13

本文综述肺动脉高压(PAH)发病机制相关的七大类新机制,包括骨形态发生蛋白信号、酪氨酸激酶受体、雌激素代谢、细胞外基质、血管新生、表观遗传和5-羟色胺代谢。文章讨论推动这些机制优先研究的临床前研究,并总结已完成和正在进行的2/3期试验,涉及sotatercept、阿那曲唑、rodatristat ethyl、酪氨酸激酶抑制剂和内皮祖细胞等新干预。

要点

  • PAH现有肺血管扩张剂不足以阻止小血管丢失和阻塞,需靶向血管新生和细胞生长/纤维化调控的新药。
  • 临床前研究识别出七大类PAH相关机制,已有多种候选药物进入2/3期临床试验。
  • 新型干预包括sotatercept、阿那曲唑、rodatristat ethyl、酪氨酸激酶抑制剂和内皮祖细胞等。

核心结论

  • 下一代化合物有望在现有标准治疗基础上改善PAH患者临床结局和生活质量。

研究设计与样本

  • 综述类文章,检索范围未在摘要中明确报告。

主要发现

  • PAH与肺压力异常升高和右心衰竭相关,致高发病率和高死亡率。
  • 肺血管扩张剂改善了PAH预后,但疾病进展仍是主要问题。
  • 现有治疗不足以预防小血管丢失和阻塞。
  • 临床前研究识别出七大类PAH相关机制并推动候选药物进入临床试验。

关键数值与推荐

  • 靶向七大类机制:骨形态发生蛋白信号、酪氨酸激酶受体、雌激素代谢、细胞外基质、血管新生、表观遗传和5-羟色胺代谢。
  • 涉及药物包括sotatercept、阿那曲唑、rodatristat ethyl、酪氨酸激酶抑制剂和内皮祖细胞等。
  • 已完成和正在进行的2/3期试验使用上述新型干预。

临床怎么用

  • 呼吸科智能体医生可关注PAH新机制靶向药物,尤其是进入2/3期试验的sotatercept等。
  • 在PAH管理中需认识到现有肺血管扩张剂的局限,即不能阻止小血管丢失和阻塞。

局限性

  • 摘要未报告综述的检索范围、纳入研究数量及具体试验结果。
  • 摘要未提供各药物疗效和安全性的具体数值。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Pulmonary arterial hypertension (PAH) is a rare disease associated with abnormally elevated pulmonary pressures and right heart failure resulting in high morbidity and mortality. Although the prognosis for patients with PAH has improved with the introduction of pulmonary vasodilators, disease progression remains a major problem. Given that available therapies are inadequate for preventing small-vessel loss and obstruction, there is active interest in identifying drugs capable of targeting angiogenesis and mechanisms involved in the regulation of cell growth and fibrosis. Among the mechanisms linked to PAH pathogenesis, preclinical studies have identified promising compounds that are currently being tested in clinical trials. These drugs target seven of the major mechanisms associated with PAH pathogenesis: bone morphogenetic protein signaling, tyrosine kinase receptors, estrogen metabolism, extracellular matrix, angiogenesis, epigenetics, and serotonin metabolism. In this review, we discuss the preclinical studies that led to prioritization of these mechanisms, and discuss completed and ongoing phase 2/3 trials using novel interventions such as sotatercept, anastrozole, rodatristat ethyl, tyrosine kinase inhibitors, and endothelial progenitor cells, among others. We anticipate that the next generation of compounds will build on the success of the current standard of care and improve clinical outcomes and quality of life for patients with PAH.

来源:Chest,查看原文。版权归原作者所有。

引用

  1. Condon DF, Agarwal S, Chakraborty A, et al. Novel Mechanisms Targeted by Drug Trials in Pulmonary Arterial Hypertension. Chest. 2021. PMID: 34655569. doi:10.1016/j.chest.2021.10.010

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。